Date: 2018-04-04
Type of information: Collaboration agreement
Compound: IgE antibodies against two undisclosed targets
Company: Iontas (UK) IGEM Therapeutics (UK)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: monoclonal antibody
Disease:
Details:
- • On April 4, 2018, Iontas announced that it will collaborate with IGEM Therapeutics , an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer. The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.
- Iontas will utilise its proprietary antibody discovery technology to help IGEM identify novel IgE antibodies against two targets. IgE antibodies have been shown to permeate tumour tissue more effectively, exhibit enhanced effector functions and stimulate significantly greater levels of cytotoxicity and phagocytosis than IgG antibodies. Iontas will apply its proprietary antibody discovery libraries and technologies to identify specific, high-affinity antibodies against two tumour-associated targets. Functional screening of IgE-formatted antibodies will be carried out to identify the most appropriate candidates for therapeutic development.
Financial terms:
Latest news:
Is general: Yes
